ArticleCureus2025
Propranolol Effective in Suppressing Paroxysmal Sympathetic Hyperactivity Attacks Occurring in the Acute Phase of Diffuse Axonal Injury: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Propranolol monotherapy versus combined propranolol-gabapentin for prevention of paroxysmal sympathetic hyperactivity after moderate-severe traumatic brain injury: a randomized controlled trial.BMC anesthesiology · 2026Trial
- Hyperbaric oxygen for paroxysmal sympathetic hyperactivity syndrome after acute carbon monoxide poisoning.Medical gas research · 2026Article
- The role of the neuro-immune-bone axis in osteoporosis: from bone remodeling imbalance to multi-system interactions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paroxysmal sympathetic hyperactivity occurs primarily after severe traumatic brain injury and is characterized by abnormal paroxysmal surges in sympathetic nervous system activity. The clinical symptoms of paroxysmal sympathetic hyperactivity may resemble those of epilepsy or sepsis, leading to delayed diagnosis and inadequate treatment. A 16-year-old male individual suffered a severe brain injury following a traffic accident. His Glasgow Coma Scale score was 4/15 (E1V1M2). Magnetic resonance imaging revealed cerebral contusion in bilateral frontal lobes, genu, and splenium of the corpus callosum, and diffuse axonal injury was diagnosed. Pharmacological therapy with medication to reduce cerebral edema, analgesics, sedatives, and antiepileptic drugs was initiated. On the 7th day, the sedatives were temporarily discontinued, the patient's limbs were held in an extended position with muscle contractions, and also exhibited hyperthermia, tachycardia, sweating, and hypertension, which lasted approximately 30 minutes and occurred multiple times a day. Blood, sputum, and urine cultures were negative, and two electroencephalograms did not detect epileptic discharges, so sepsis and epilepsy were excluded. Baclofen and dantrolene slightly improved muscle stiffness, but the continuous intravenous infusion of sedatives could not be discontinued for more than 40 days because it caused a recurrence of attacks. Propranolol 30 mg/day was added, and paroxysmal sympathetic hyperactivity attacks disappeared. Therefore, sedatives could be discontinued and the patient was transferred to a rehabilitation hospital. Propranolol, an oral β-adrenergic blocker, is one of the effective treatments for paroxysmal sympathetic hyperactivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.